Abstract

To better understand a role of eIF4E S209 in oncogenic translation, we generated EIF4ES209A/+ heterozygous knockin (4EKI) HCT 116 human colorectal cancer (CRC) cells. 4EKI had little on total eIF4E levels, cap binding or global translation, while markedly reduced HCT 116 cell growth in spheroids and mice, and CRC organoid growth. 4EKI strongly inhibited Myc and ATF4 translation, the integrated Stress Response (ISR)-dependent glutamine metabolic signature, AKT activation and proliferation in vivo. 4EKI inhibited polyposis in ApcMin/+ mice by suppressing Myc protein and AKT activation. Furthermore, p-eIF4E was highly elevated in CRC precursor lesions in mouse and human. p-eIF4E cooperated with mutant KRAS to promote Myc and ISR-dependent glutamine addiction in various CRC cell lines, characterized by increased cell death, transcriptomic heterogeneity and immune suppression upon deprivation. These findings demonstrate a critical role of eIF4E S209-dependent translation in Myc and stress-driven oncogenesis and as a potential therapeutic vulnerability.

Data availability

Microarray data is deposited in Dryad under doi:10.5061/dryad.tb2rbnzxm.All data generated or analyzed during this study are included in the manuscript and supporting files.

The following data sets were generated
    1. YU
    2. Jian
    (2020) Microarray data
    Dryad Digital Repository, doi:10.5061/dryad.tb2rbnzxm.

Article and author information

Author details

  1. Hang Ruan

    Pathology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  2. Xiangyun Li

    Pathology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  3. Xiang Xu

    Stem Cell and Regenerative Medicine, Daping Hospital, Chongqing, China
    Competing interests
    No competing interests declared.
  4. Brian J Leibowitz

    Pathology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  5. Jingshan Tong

    Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  6. Lujia Chen

    Medical Informatics, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  7. Luoquan Ao

    Stem Cell and Regenerative Medicine, Daping Hospital, Chongqing, China
    Competing interests
    No competing interests declared.
  8. Wei Xing

    Stem Cell and Regenerative Medicine, Daping Hospital, Chongqing, China
    Competing interests
    No competing interests declared.
  9. Jianhua Luo

    Pathology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  10. Yanping Yu

    Pathology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  11. Robert E Schoen

    Medicine, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  12. Nahum Sonenberg

    Goodman Cancer Research Center, McGill University, Montreal, Canada
    Competing interests
    Nahum Sonenberg, Reviewing editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4707-8759
  13. Xinghua Lu

    Biomedical Informatics, University of Pittsburgh, Pittsbrugh, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8599-2269
  14. Lin Zhang

    Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  15. Jian Yu

    Pathology, University of Pittsburgh, Pittsburgh, United States
    For correspondence
    yuj2@upmc.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4021-1000

Funding

NIH (R01CA215481)

  • Jian Yu

NIH (R01CA172136)

  • Lin Zhang

NIH (R01CA203028)

  • Lin Zhang

NIH (R01CA236271)

  • Lin Zhang

NIH (R01LM012011)

  • Xinghua Lu

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (# 19085635 and 18063020) of the University of Pittsburgh. All animal experiments were approved by the University of Pittsburgh Institutional Animal Care and Use Committee under Animal welfare assurance number A-3187-01. No surgery or invasive procedure was performed and every effort was made to minimize suffering with humane sacrifice.

Copyright

© 2020, Ruan et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,343
    views
  • 358
    downloads
  • 25
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Hang Ruan
  2. Xiangyun Li
  3. Xiang Xu
  4. Brian J Leibowitz
  5. Jingshan Tong
  6. Lujia Chen
  7. Luoquan Ao
  8. Wei Xing
  9. Jianhua Luo
  10. Yanping Yu
  11. Robert E Schoen
  12. Nahum Sonenberg
  13. Xinghua Lu
  14. Lin Zhang
  15. Jian Yu
(2020)
eIF4E S209 phosphorylation licenses Myc-and stress-driven oncogenesis
eLife 9:e60151.
https://doi.org/10.7554/eLife.60151

Share this article

https://doi.org/10.7554/eLife.60151

Further reading

    1. Cancer Biology
    Pierluigi Scerbo, Benjamin Tisserand ... Bertrand Ducos
    Research Article

    Why does a normal cell possibly harboring genetic mutations in oncogene or tumor suppressor genes becomes malignant and develops a tumor is a subject of intense debate. Various theories have been proposed but their experimental test has been hampered by the unpredictable and improbable malignant transformation of single cells. Here, using an optogenetic approach we permanently turn on an oncogene (KRASG12V) in a single cell of a zebrafish brain that, only in synergy with the transient co-activation of a reprogramming factor (VENTX/NANOG/OCT4), undergoes a deterministic malignant transition and robustly and reproducibly develops within 6 days into a full-blown tumor. The controlled way in which a single cell can thus be manipulated to give rise to cancer lends support to the ‘ground state theory of cancer initiation’ through ‘short-range dispersal’ of the first malignant cells preceding tumor growth.

    1. Cancer Biology
    Han V Han, Richard Efem ... Richard Z Lin
    Research Article

    Most human pancreatic ductal adenocarcinoma (PDAC) are not infiltrated with cytotoxic T cells and are highly resistant to immunotherapy. Over 90% of PDAC have oncogenic KRAS mutations, and phosphoinositide 3-kinases (PI3Ks) are direct effectors of KRAS. Our previous study demonstrated that ablation of Pik3ca in KPC (KrasG12D; Trp53R172H; Pdx1-Cre) pancreatic cancer cells induced host T cells to infiltrate and completely eliminate the tumors in a syngeneic orthotopic implantation mouse model. Now, we show that implantation of Pik3ca−/− KPC (named αKO) cancer cells induces clonal enrichment of cytotoxic T cells infiltrating the pancreatic tumors. To identify potential molecules that can regulate the activity of these anti-tumor T cells, we conducted an in vivo genome-wide gene-deletion screen using αKO cells implanted in the mouse pancreas. The result shows that deletion of propionyl-CoA carboxylase subunit B gene (Pccb) in αKO cells (named p-αKO) leads to immune evasion, tumor progression, and death of host mice. Surprisingly, p-αKO tumors are still infiltrated with clonally enriched CD8+ T cells but they are inactive against tumor cells. However, blockade of PD-L1/PD1 interaction reactivated these clonally enriched T cells infiltrating p-αKO tumors, leading to slower tumor progression and improve survival of host mice. These results indicate that Pccb can modulate the activity of cytotoxic T cells infiltrating some pancreatic cancers and this understanding may lead to improvement in immunotherapy for this difficult-to-treat cancer.